Ramucirumab Plus Pemetrexed and Platinum Chemotherapy Shows Clinical Activity in Advanced Nonsquamous NSCLC

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal Cancer, researchers have found that ramucirumab demonstrated clinical activity in combination with pemetrexed plus carboplatin or cisplatin in patients with nonsquamous non-small cell lung cancer (NSCLC).

For the open-label, phase 2 study, researchers enrolled 140 patients with stage 4 nonsquamous NSCLC who had not received prior chemotherapy for metastatic disease.


Researchers randomly assigned participants to receive pemetrexed plus carboplatin or cisplatin with or without ramucirumab 10mg/kg once every 3 weeks for four to six cycles, followed by a maintenance phase with pemetrexed with or without ramucirumab.

Results showed a median progression-free survival of 5.6 months for patients who received pemetrexed plus platinum versus 7.2 months for those who received pemetrexed, platinum, and ramucirumab (HR = 0.75; P = 0.132). Patients in the pemetrexed-platinum arm had a objective response rate of 38.0% compared with 49.3% in the ramucirumab arm (P = 0.180).

The disease control rate was 70.4% and 85.5% for the pemetrexed-platinum and ramucirumab arms, respectively (P = 0.032). The most common grade 3 or higher adverse effects were anemia, back pain, fatigue, hypertension, neutropenia, and thrombocytopenia. Ultimately, the primary endpoint of progression-free survival was not met.

Medicare to Pay for Early Lung Cancer Screening for Qualified Individuals
Ramucirumab demonstrated clinical activity with pemetrexed in patients with nonsquamous NSCLC.
This phase 2 study investigated ramucirumab in combination with first–line pemetrexed and platinum chemotherapy in advanced/metastatic NSCLC

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs